PMID- 36992131
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231106
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 11
IP  - 3
DP  - 2023 Feb 25
TI  - HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review.
LID - 10.3390/vaccines11030548 [doi]
LID - 548
AB  - The adaptive (T-cell-mediated) immune response is a key player in determining the 
      clinical outcome, in addition to neutralizing antibodies, after SARS-CoV-2 
      infection, as well as supporting the efficacy of vaccines. T cells recognize 
      viral-derived peptides bound to major histocompatibility complexes (MHCs) so that 
      they initiate cell-mediated immunity against SARS-CoV-2 infection or can support 
      developing a high-affinity antibody response. SARS-CoV-2-derived peptides bound 
      to MHCs are characterized via bioinformatics or mass spectrometry on the whole 
      proteome scale, named immunopeptidomics. They can identify potential vaccine 
      targets or therapeutic approaches for SARS-CoV-2 or else may reveal the 
      heterogeneity of clinical outcomes. SARS-CoV-2 epitopes that are naturally 
      processed and presented on the human leukocyte antigen class I (HLA-I) and class 
      II (HLA-II) were identified for immunopeptidomics. Most of the identified 
      SARS-CoV-2 epitopes were canonical and out-of-frame peptides derived from spike 
      and nucleocapsid proteins, followed by membrane proteins, whereby many of which 
      are not caught by existing vaccines and could elicit effective responses of T 
      cells in vivo. This review addresses the detection of SARS-CoV-2 viral epitopes 
      on HLA-I and HLA-II using bioinformatics prediction and mass spectrometry (HLA 
      peptidomics). Profiling the HLA-I and HLA-II peptidomes of SARS-CoV-2 is also 
      detailed.
FAU - Abd El-Baky, Nawal
AU  - Abd El-Baky N
AUID- ORCID: 0000-0002-1738-2274
AD  - Protein Research Department, Genetic Engineering and Biotechnology Research 
      Institute (GEBRI), City of Scientific Research and Technological Applications 
      (SRTA-City), New Borg El-Arab City, Alexandria P.O. Box 21934, Egypt.
FAU - Amara, Amro A
AU  - Amara AA
AD  - Protein Research Department, Genetic Engineering and Biotechnology Research 
      Institute (GEBRI), City of Scientific Research and Technological Applications 
      (SRTA-City), New Borg El-Arab City, Alexandria P.O. Box 21934, Egypt.
FAU - Redwan, Elrashdy M
AU  - Redwan EM
AD  - Biological Sciences Department, Faculty of Science, King Abdulaziz University, 
      Jeddah P.O. Box 80203, Saudi Arabia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230225
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC10058130
OTO - NOTNLM
OT  - HLA-I
OT  - HLA-II
OT  - MHCs
OT  - SARS-CoV-2
OT  - T-cell-mediated immunity
OT  - immunopeptidomics
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/31 06:00
MHDA- 2023/03/31 06:01
PMCR- 2023/02/25
CRDT- 2023/03/30 01:04
PHST- 2023/01/29 00:00 [received]
PHST- 2023/02/18 00:00 [revised]
PHST- 2023/02/23 00:00 [accepted]
PHST- 2023/03/31 06:01 [medline]
PHST- 2023/03/30 01:04 [entrez]
PHST- 2023/03/31 06:00 [pubmed]
PHST- 2023/02/25 00:00 [pmc-release]
AID - vaccines11030548 [pii]
AID - vaccines-11-00548 [pii]
AID - 10.3390/vaccines11030548 [doi]
PST - epublish
SO  - Vaccines (Basel). 2023 Feb 25;11(3):548. doi: 10.3390/vaccines11030548.